These findings are supported by previous works that described the importance of addressing the JAK/STAT pathway [25], aging-related neuroinflammation [26], and use of inhibitors against components of the pathways related to EGF [74], PDGF-BB [75], MAPK [75], or relevant cytokine receptors [76,77,78,79], as potentially ways to counter AD. Here, EGF is linked to Alzheimer disease.